UTHR News and Press, United Therapeutics Corporation From 06/27/22

Benefit corporations are a new form of business and increasing in number on the market. Similar to ESG metrics, these companies often take it many steps further in regards to positivity. The business structure allows some profits to be syphoned away towards beneficial endeavors, w...

United Therapeutics broke out to the upside. Stock price doubled since bottoming in 2019. Strong prospects from clinical studies discussed. For further details see: Why Hold United Therapeutics After Shares Doubled?

Lung scaffolds developed in partnership with 3D Systems Corporation represent the most complex objects ever printed; reveal took place at the LIFE ITSELF Conference in San Diego 3D-printed lung scaffolds are demonstrating gas exchange in animal models United Therapeuti...

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Jefferies Healthcare Conference in New York City. ...

The major U.S. equity averages scored another day of notable gains, continuing a rebound that started midway through the week. The Nasdaq led the charge with a 3% advance, as the S&P 500 broke its seven-week-long weekly losing streak. Tech stocks were among the drivers of Friday's rally, ...

Bank of America launched its coverage on Liquidia Corporation (NASDAQ:LQDA) with a Buy rating after the developer of lung disease drug Yutrepia recently suffered a major setback when a rival therapy from United Therapeutics (UTHR) and MannKind (MNKD) won the FDA approval. The company shares p...

Credit Suisse increased the price target on the commercial-stage biotech United Therapeutics (NASDAQ:UTHR) after the company and its partner MannKind (MNKD) won the U.S. approval for inhalational therapy Tyvaso DPI for two lung indications. With an Outperform rating on United (UTHR), the...

The U.S. Food and Drug Administration (FDA) approved United Therapeutics (NASDAQ:UTHR) Tyvaso DPI (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. PAH...

First approval of a dry powder inhaler for treatment of PAH and PH-ILD DPI device represents a convenient option for administration of treprostinil therapy Commercial launch activities underway; patient availability expected in June 2022 United Therapeutics C...

Commercial-stage biotech, United Therapeutics (NASDAQ:UTHR) and its partner MannKind (MNKD) are trading sharply higher on Monday after the FDA announced the approval of their lung disease therapy Tyvaso DPI. Accordingly, the drug-device combination is authorized to treat the pulmonary arteria...